Trial Outcomes & Findings for Remifentanil in Deep vs Moderate Neuromuscular Blocks During Surgical Pleth Index-guided Anesthesia for Laparoscopic Herniorrhaphy (NCT NCT04022733)

NCT ID: NCT04022733

Last Updated: 2023-11-09

Results Overview

remifentanil infusion using target effect-site concentration to achieve an surgical pleth index of range between 25 and 50

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

134 participants

Primary outcome timeframe

from pneumoperitoneum to removal of laparoscope, an average of 30 minutes

Results posted on

2023-11-09

Participant Flow

Participant milestones

Participant milestones
Measure
Moderate NMB Group
Moderate neuromuscular block: maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
Deep NMB Group
Deep neuromuscular block: maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
Overall Study
STARTED
67
67
Overall Study
COMPLETED
64
64
Overall Study
NOT COMPLETED
3
3

Reasons for withdrawal

Reasons for withdrawal
Measure
Moderate NMB Group
Moderate neuromuscular block: maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
Deep NMB Group
Deep neuromuscular block: maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
Overall Study
conversion to open surgery
3
2
Overall Study
bradycardia
0
1

Baseline Characteristics

Remifentanil in Deep vs Moderate Neuromuscular Blocks During Surgical Pleth Index-guided Anesthesia for Laparoscopic Herniorrhaphy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Moderate NMB Group
n=64 Participants
Moderate neuromuscular block: maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
Deep NMB Group
n=64 Participants
Deep neuromuscular block: maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
Total
n=128 Participants
Total of all reporting groups
Age, Continuous
63 year
n=99 Participants
65 year
n=107 Participants
63.5 year
n=206 Participants
Sex: Female, Male
Female
6 Participants
n=99 Participants
5 Participants
n=107 Participants
11 Participants
n=206 Participants
Sex: Female, Male
Male
58 Participants
n=99 Participants
59 Participants
n=107 Participants
117 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
64 Participants
n=99 Participants
64 Participants
n=107 Participants
128 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
White
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
South Korea
64 participants
n=99 Participants
64 participants
n=107 Participants
128 participants
n=206 Participants

PRIMARY outcome

Timeframe: from pneumoperitoneum to removal of laparoscope, an average of 30 minutes

remifentanil infusion using target effect-site concentration to achieve an surgical pleth index of range between 25 and 50

Outcome measures

Outcome measures
Measure
Moderate NMB Group
n=64 Participants
Moderate neuromuscular block: maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
Deep NMB Group
n=64 Participants
Deep neuromuscular block: maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
Remifentanil Infusion Rate
0.103 µg/kg/min
Interval 0.075 to 0.143
0.073 µg/kg/min
Interval 0.056 to 0.097

Adverse Events

Moderate NMB Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Deep NMB Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Associate professor in Anesthesiology Department

Ajou University

Phone: 82-31-2195689

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place